Naresh Nagella, MD
Pulmonary Disease · Pennington, NJNPI 1497068803
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,378 of the $80,468 with a category attached, or 78.8%. AstraZeneca accounts for 75.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $62,994, more than ten times the $42 reported in 2019. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $540.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$60K
- Sanofi$14K
- GSK$6K
- Regeneron Healthcare Solutions, Inc.$263
- Boehringer Ingelheim$112
- Insmed, Inc.$97
- plus $201 from 6 others
What the payments were for
- Consulting fees$5,0156%
- Speaking & faculty fees$63,37879%
- Travel & lodging$7,6079%
- Food & beverage$4,2675%
- Education$2020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $60,332 |
| Sanofi | 18 | $13,645 |
| GSK | 25 | $5,818 |
| Regeneron Healthcare Solutions, Inc. | 6 | $263 |
| Boehringer Ingelheim | 7 | $112 |
| Insmed, Inc. | 3 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Philips North America LLC | 2 | $43 |
| Baxter Healthcare | 2 | $34 |
| Amgen | 1 | $34 |
| Merck | 1 | $15 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,468 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 76 | $336,888 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 394 | $311,954 |
| Dupixent PenDupilumab | 67 | $286,601 |
| OfevNintedanib Esylate | 16 | $205,240 |
| Fasenra PenBenralizumab | 17 | $96,422 |
| NucalaMepolizumab | 23 | $77,989 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $73,433 |
| Dupixent SyringeDupilumab | 18 | $67,351 |
| Breo ElliptaFluticasone/Vilanterol | 133 | $61,243 |
| Incruse ElliptaUmeclidinium Bromide | 58 | $31,323 |
| Spiriva RespimatTiotropium Bromide | 34 | $22,536 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $19,259 |
| Varenicline Tartrate | 41 | $10,552 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $9,367 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $8,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $5,818 | $489,795620 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $60,332 | $416,811193 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $112 | $253,104102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Pennington
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.